TBPH Q3 2024 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+7.5% YoY

Gross Profit

$8M45.1% margin

Operating Income

-$11M-64.2% margin

Net Income

-$13M-75.3% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+18.3%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$356M

Total Liabilities

$170M

Stockholders' Equity

$186M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$16M	+7.5%
Gross Profit	$8M	$14M	-47.1%
Operating Income	-$11M	-$9M	-23.7%
Net Income	-$13M	-$9M	-41.9%

Revenue Segments

YUPELRI Monotherapy

$22M56%

Collaboration revenue

$17M44%